Background: Leukemia is a severe type of blood cancer that involves an abnormal proliferation of blood-forming cells. Its conventional treatment faces many challenges, including resistance, lack of specificity and high unwanted toxicity of drugs. Nano drug delivery systems help in overcoming these challenges by delivering the drug to the target site actively or passively. Solid lipid nanoparticles are gaining popularity because they reduce unwanted toxicity, are biocompatible, increase bioavailability and are versatile in terms of incorporated agents (hydrophilic as well as lipophilic drugs, genes, enzymes, etc.).
Purpose: The aim of this review is to discuss recent advancements in anti-leukemic therapy utilizing solid lipid nanoparticles (SLNs) as successful carriers in enhancing the efficiency of the treatment and bioavailability of the incorporated drug along with overcoming multidrug resistance.
Methods: This review represents the existing literature on the applications of SLNs in anti-leukemic therapy. A qualitative literature review has been performed for this purpose. We performed keyword research in popular databases such as Google Scholar, Wiley, Elsevier, Scopus, Google patent and PubMed. Only articles published in English and from reputed journals from specific fields were considered. Benchmark studies having major importance from 2000 to 2020 were selected to follow the progress in the field across the globe.
Results: This article improves the understanding of the role of SLNs in the treatment of leukemia. Traditional anti-leukemic therapy involves many challenges, including resistance, lack of specificity and high unwanted toxicity of drugs. SLNs are emerging as a better alternative to conventional delivery systems as they can reduce unwanted toxicity, are biocompatible, and can provide active as well as passive molecular targeting.
Conclusion: SLNs provide several advantages in drug delivery for leukemia, including enhancement of efficiency and bioavailability and reduction of toxicity by virtue of their small size, lipid core, non-dependency on organic solvents and versatility in terms of incorporated drugs.
[http://dx.doi.org/10.3390/pharmaceutics11040163] [PMID: 30987266]
[http://dx.doi.org/10.1016/j.ejpb.2014.05.004] [PMID: 24833004]
[http://dx.doi.org/10.1021/nn2005766] [PMID: 21675727]
[http://dx.doi.org/10.2217/nnm-2016-0380] [PMID: 28186465]
[http://dx.doi.org/10.1016/j.colsurfb.2017.03.021] [PMID: 28334689]
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00846] [PMID: 29341619]
[http://dx.doi.org/10.1055/s-0043-102404] [PMID: 28288490]
[http://dx.doi.org/10.1016/j.ijpharm.2018.07.014] [PMID: 30033394]
[http://dx.doi.org/10.1111/j.2042-7158.2010.01024.x] [PMID: 21039547]
[http://dx.doi.org/10.1016/j.foodres.2019.108720] [PMID: 31882083]
[http://dx.doi.org/10.1039/C4NR01510J] [PMID: 25003978]
[http://dx.doi.org/10.1007/s00277-019-03713-y] [PMID: 31104089]
[http://dx.doi.org/10.1038/mt.2013.210]] [PMID: 24002693]
[http://dx.doi.org/10.1002/jbm.a.36837] [PMID: 31714657]
[http://dx.doi.org/10.1097/01.cad.0000127329.83568.15] [PMID: 15166628]
[http://dx.doi.org/10.1021/mp300385m] [PMID: 23237302]
[http://dx.doi.org/10.1016/j.jconrel.2011.08.004] [PMID: 21851843]
[http://dx.doi.org/10.2147/DDDT.S202818] [PMID: 31388296]
[http://dx.doi.org/10.1016/j.biopha.2016.11.121] [PMID: 28024291]